Antisense Technology

Patent Received on Antisense Inhibitor of C-raf Kinase

Published in Cancer Weekly, October 21st, 1996

Isis Pharmaceuticals, Carlsbad, California, has received a U.S. patent for ISIS 5132/CGP69846A, an antisense inhibitor of C-raf kinase.

The patent covers numerous antisense sequences targeted to C-raf kinase, most notable of which is the sequence of ISIS 5132/CGP69846A, and includes broad claims covering analogs of these compounds incorporating a variety of novel chemical modifications which have the potential to produce antisense compounds with enhanced potency and safety and altered pharmacokinetics.

The inventors on the patent were Brett P. Monia, Ph.D., and Russell Boggs, Ph.D., Isis. ISIS 5132/CGP69846A has been in Phase I clinical trials as a...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1996-10-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry